Citations

Clear

626 citation(s) found for "Mehta, SH".

Updates in the management of intradural spinal cord tumors: a radiation oncology focus
Kotecha, Rupesh , Chang, Eric L. , Brown, Paul D. , Lo, Simon S. , Samawi, Haider , Keith, Julia , Perry, James , Sahgal, Arjun , Mehta, Minesh P. , Suh, John H. , Das, Sunit

Mayo Clinic

Neuro-Oncology | January 14, 2019 | Volume: 21 | Issue: 6 | Pages: 707-718

10.1093/neuonc/noz014 | PMID 30977511 Get It

Abstract Primary spinal cord tumors represent a hetereogeneous group of central nervous system malignancies whose management is complex given the relatively uncommon nature of the disease and variety of tumor subtypes, functional neurologic deficits from the tumor, and potential morbidities associated with definitive treatment. Advances in neuroimaging; integration of diagnostic, prognostic, and predictive molecular testing into tumor classification; and developments in neurosurgical techniques have refined the current role of radiotherapy in the multimodal management of patients with primary spinal cord tumors, and corroborated the need for prospective, multidisciplinary discussion and treatment decision making. Radiotherapeutic technological advances have dramatically improved the entire continuum from treatment planning to treatment delivery, and the development of stereotactic radiosurgery and proton radiotherapy provides new radiotherapy options for patients treated in the definitive, adjuvant, or salvage setting. The objective of this comprehensive review is to provide a contemporary overview of the management of primary intradural spinal cord tumors, with a focus on radiotherapy.
Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era
Gerson, James N. , Villa, Diego , Gerrie, Alina S. , Chapani, Parv , Medeiros, L. Jeffrey , Wang, Michael I., Cohen, Jonathon B. , Calzada, Oscar , Churnetski, Michael C. , Hill, Brian T. , Sawalha, Yazeed , Hernandez‐Ilizaliturri, Francisco J. , Kothari, Shalin , Bast, Martin, Fenske, Timothy S. , Gari, Swapna Narayana Rao, Maddocks, Kami J. , Bond, David A. , Bachanová, Veronika , Kolla, Bhaskar , Lansigan, Frederick , Donovan, Alexandra M., Wagner‐Johnston, Nina D. , Messmer, Marcus , Anderson, Jennifer K., Reddy, Nishitha , Kovach, Alexandra E. , Glenn, Martha, Inwards, David J. , Karmali, Reem , Kaplan, Jason , Rajguru, Saurabh, Evens, Andrew M. , Klein, Andreas K. , Umyarova, Elvira , Pulluri, Bhargavi , Amengual, Jennifer E. , Diefenbach, Catherine , Fisher, Richard I., Bachanova, Veronika , Sawalha, Yazeed , Gerrie, Alina S , Evens, Andrew M , Karmali, Reem , Bond, David A , Medeiros, L Jeffrey , Lansigan, Frederick , Diefenbach, Catherine S , Kovach, Alexandra E , Handorf, Elizabeth A. , Li, Shaoying , Vose, Julie M. , Chavez, Julio C , Shah, Bijal , Burns, Timothy Francis , Mehta, Amitkumar , Landsburg, Daniel J. , Caimi, Paolo F. , Lue, Jennifer Kimberly , Barta, Stefan K

Mayo Clinic

Journal of Clinical Oncology | January 7, 2019 | Volume: 37 | Issue: 6 | Pages: 471-480

10.1200/jco.18.00690 | PMID 30615550 Get It

PURPOSE Mantle cell lymphoma (MCL) is a B-cell lymphoma characterized by cyclin D1 expression. Autologous hematopoietic cell transplantation (AHCT) consolidation after induction chemotherapy is often used for eligible patients; however, the benefit remains uncertain in the rituximab era. Herein we retrospectively assessed the impact of AHCT consolidation on survival in a large cohort of transplantation-eligible patients age 65 years or younger. PATIENTS AND METHODS We retrospectively studied transplantation-eligible adults age 65 years or younger with newly diagnosed MCL treated between 2000 and 2015. The primary objective was to assess for improved progression-free survival (PFS) with AHCT consolidation and secondarily to assess for improved overall survival (OS). Cox multivariable regression analysis and propensity score–weighted (PSW) analysis were performed. RESULTS Data were collected from 25 medical centers for 1,254 patients; 1,029 met inclusion criteria. Median follow-up for the cohort was 76 months. Median PFS and OS were 62 and 139 months, respectively. On unadjusted analysis, AHCT was associated with improved PFS (75 v 44 months with v without AHCT, respectively; P < .01) and OS (147 v 115 months with v without AHCT, respectively; P < .05). On multivariable regression analysis, AHCT was associated with improved PFS (hazard ratio [HR], 0.54; 95% CI, 0.44 to 0.66; P < .01) and a trend toward improved OS (HR, 0.77; 95% CI, 0.59 to 1.01; P = .06). After PSW analysis, AHCT remained associated with improved PFS (HR, 0.70; 95% CI, 0.59 to 0.84; P < .05) but not improved OS (HR, 0.87; 95% CI, 0.69 to 1.1; P = .2). CONCLUSION In this large cohort of younger, transplantation-eligible patients with MCL, AHCT consolidation after induction was associated with significantly improved PFS but not OS after PSW analysis. Within the limitations of a retrospective analysis, our findings suggest that in younger, fit patients, AHCT consolidation may improve PFS.
Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and vincristine (PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG.
Buckner, Jan C. , Pugh, Stephanie L. , Shaw, Edward G. , Barger, Geoffrey, Coons, Stephen W., Ricci, Peter E. , Bullard, Dennis E., Brown, Paul D. , Stelzer, K. , Brachman, David, Schultz, Christopher J. , Bahary, Jean-Paul , Fisher, Barbara J., Kim, Harold , Murtha, Albert , Curran, Walter J. , Gilbert, Mark R. , Suh, John H. , Mehta, Minesh P.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 2000-2000

10.1200/jco.2014.32.15_suppl.2000 Get It

595: SPONTANEOUS BRONCHOPERITONEAL FISTULA IN THE SETTING OF ARDS
Mehta, Gautum, Sims, Charles R.

Mayo Clinic

Critical Care Medicine | December 18, 2018 | Volume: 47 | Issue: 1 | Pages: 278-278

10.1097/01.ccm.0000551347.61371.ae Get It

B cell homeostasis is maintained during long-duration spaceflight
Spielmann, Guillaume , Agha, Nadia H. , Kunz, Hawley , Simpson, Richard J. , Crucian, Brian, Mehta, Satish , Campbell, John P. , Simpson, Richard J , Kunz, Hawley E , Laughlin, Mitzi S.

Mayo Clinic

Journal of Applied Physiology | November 29, 2018 | Volume: 126 | Issue: 2 | Pages: 469-476

10.1152/japplphysiol.00789.2018 | PMID 30496712 Get It

Long-duration spaceflights reportedly induce immune dysregulation, which is considered a risk to astronaut safety and mission success. Recent studies have examined the impact of spaceflight on markers of adaptive and innate immunity, but no study, to date, has comprehensively evaluated humoral immunity and serological markers of B cell function. The aim of this study was to characterize changes in B cell numbers and phenotypes, along with plasma Igs and polyclonal free light chains (FLCs)—near-“real-time” biomarkers of Ig synthesis—in response to an ~6-mo mission to the International Space Station (ISS). Whole-blood samples were collected before flight, during flight (“Early flight,” “Mid-flight,” and “Late flight”), immediately upon return, and during a recovery period (R + 18, R + 30/R + 33, and R + 60/R + 66) from 23 ISS crew members. B Cell counts and phenotypes were measured throughout the duration of the mission, along with total plasma Ig and FLC levels. There was no effect of spaceflight on the number and proportion of the different B cell subsets. There was no difference in kappa FLC between preflight samples and either in-flight or recovery samples ( P > 0.05), and only a marginal reduction was observed in lambda FLC levels upon return to Earth ( P < 0.05). Furthermore, IgG and IgM remained unchanged during and after spaceflight compared with preflight values ( P > 0.05). Of note, plasma IgA concentrations were elevated in-flight compared with baseline and recovery values ( P < 0.05). These results indicate that B cell homeostasis is maintained during long-duration spaceflight, advocating for potential in-flight vaccination as viable countermeasures against viral reactivation during exploration-class missions.
The Timing Hypothesis: Hormone Therapy for Treating Symptomatic Women During Menopause and Its Relationship to Cardiovascular Disease
Mehta, Jaya , Chester, Rebecca , Kling, Juliana M. , Mehta, Jaya M, Chester, Rebecca C, Kling, Juliana M

Mayo Clinic

Journal of Women's Health | November 28, 2018 | Volume: 28 | Issue: 5 | Pages: 705-711

10.1089/jwh.2018.7201 | PMID 30484736 Get It

The risks and benefits of menopausal hormonal therapy (HT) have been evaluated extensively over the past three decades. While the efficacy of HT for management of menopausal symptoms, including vasomotor symptoms and vaginal dryness is well established, its relationship to cardiovascular outcomes is complex. The timing hypothesis, which posits that the cardiovascular effects of HT depend on the timing of initiation of HT in relation to menopause, has helped shape our understanding of the cardiovascular outcomes related to HT. Based on results from female monkey studies, the timing hypothesis provides a framework to explain discrepancies in results between multiple observation studies and the Women's Health Initiative (WHI) hormone therapy trials. The WHI trials closed early in 2002 in part because of increased cardiovascular events seen in women on treatment. Subanalysis of the WHI results by age group, and more recent randomized control studies, including the Kronos Early Estrogen and Prevention Study (KEEPS) and Early Versus Late Intervention Trial (ELITE), demonstrate that the risk of adverse cardiovascular events for HT are low for women <60 years of age or within 10 year from menopause. Although current data does not support using HT for primary prevention of cardiovascular disease, it does suggest that HT can be safely used to treat symptoms in appropriately selected women close to menopause.
NCOG-01. PRESERVATION OF NEUROCOGNITIVE FUNCTION (NCF) WITH HIPPOCAMPAL AVOIDANCE DURING WHOLE-BRAIN RADIOTHERAPY (WBRT) FOR BRAIN METASTASES: PRELIMINARY RESULTS OF PHASE III TRIAL NRG ONCOLOGY CC001
Gondi, Vinai , Pugh, Stephanie L. , Brown, Paul D. , Bovi, Joseph , Benzinger, Tammie, Khuntia, Deepak , Grosshans, David R. , Konski, André , Robidoux, André, Devisetty, Kiran , Shah, Sunjay, Usuki, Kenneth Y., Anderson, Bethany , Yoon, Harold, Li, Jing , Chmura, Steven J. , Kachnic, Lisa A. , Wefel, Jeffrey S. , Gilbert, Mark R. , Robinson, Clifford G. , Benzinger, Tammie L S , Tomé, Wolfgang A. , Armstrong, Terri S. , Bruner, Deborah Watkins , Kundapur, Vijayananda , Stea, Baldassarre , Laack, Nadia N. , Kruser, Tim J. , Shi, Wenyin , Mehta, Minesh P.

Mayo Clinic

Neuro-Oncology | November 5, 2018 | Volume: 20 | Issue: suppl_6 | Pages: vi172-vi172

10.1093/neuonc/noy148.716 Get It

RBTT-05. TUMOR TREATING FIELDS AND RADIOSURGERY FOR SUPRA- AND/OR INFRATENTORIAL BRAIN METASTASES (1–10) FROM NSCLC IN THE PHASE 3 METIS STUDY
Gondi, Vinai , Ahluwalia, Manmeet S. , Brown, Paul D. , Ahluwalia, Manmeet S , Mehta, Minesh P.

Mayo Clinic

Neuro-Oncology | November 5, 2018 | Volume: 20 | Issue: suppl_6 | Pages: vi235-vi235

10.1093/neuonc/noy148.975 Get It

ACTR-02. NRG ONCOLOGY/RTOG 0424: LONG-TERM RESULTS OF A PHASE II STUDY OF TEMOZOLOMIDE-BASED CHEMORADIOTHERAPY REGIMEN FOR HIGH-RISK LOW-GRADE GLIOMAS
Fisher, Barbara, Macdonald, David , Chakravarti, Arnab , Lesser, Glenn J. , Fox, Sherry, Coons, Stephen W., Rogers, Leland , Werner‐Wasik, Maria, Doyle, Thomas J. , Bahary, Jean-Paul , Fiveash, John B. , Bovi, Joseph , Howard, Steven , Yu, Michael , D’Souza, David , Roach, Mack , Kwok, Young , Wahl, Daniel , Stasser, John, Won, Minhee , Zhang, Peixin, Fox, Sherry, Laack, Nadia N. , Mehta, Minesh P.

Mayo Clinic

Neuro-Oncology | November 5, 2018 | Volume: 20 | Issue: suppl_6 | Pages: vi11-vi11

10.1093/neuonc/noy148.039 Get It

The Road to Wellness: Engagement Strategies to Help Radiologists Achieve Joy at Work
Fishman, Michael , Siewert, Bettina , Bender, Claire E., Kruskal, Jonathan B. , Fishman, Michael D C, Mehta, Tejas S, Siewert, Bettina , Kruskal, Jonathan B , Mehta, Tejas S.

Mayo Clinic

RadioGraphics | October 10, 2018 | Volume: 38 | Issue: 6 | Pages: 1651-1664

10.1148/rg.2018180030 | PMID 30303794 Get It